The SSRIs fluoxetine, paroxetine, sertraline and citalopram were reported to exhibit safety and efficacy for treatment of depression in children and adolescents. Reanalysis of published and ...
While Rejoyn is approved for depression, "it is not designed as a standalone treatment," says King; the approval is as a supplement to existing treatments or therapy to improve their effectiveness.